These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 18564305)

  • 1. Patient selection critical for calcineurin inhibitor withdrawal in pediatric kidney transplantation.
    Weintraub L; Li L; Kambham N; Alexander S; Concepcion W; Miller K; Wong C; Salvatierra O; Sarwal M
    Pediatr Transplant; 2008 Aug; 12(5):541-9. PubMed ID: 18564305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences in proteinuria and graft function in de novo sirolimus-based vs. calcineurin inhibitor-based immunosuppression in live donor kidney transplantation.
    Stephany BR; Augustine JJ; Krishnamurthi V; Goldfarb DA; Flechner SM; Braun WE; Hricik DE; Dennis VW; Poggio ED
    Transplantation; 2006 Aug; 82(3):368-74. PubMed ID: 16906035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy.
    Falger JC; Mueller T; Arbeiter K; Boehm M; Regele H; Balzar E; Aufricht C
    Pediatr Transplant; 2006 Jun; 10(4):474-8. PubMed ID: 16712606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
    Uslu A; Töz H; Sen S; Alkan FT; Nart A; Aykas A; Doğan M; Postaci H; Sahin T; Simşek C
    Transplant Proc; 2009 Mar; 41(2):756-63. PubMed ID: 19328973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calcineurin inhibitor substitution with sirolimus vs. reduced-dose calcineurin inhibitor plus sirolimus is associated with improved renal dysfunction in heart transplant patients.
    Potter BJ; Giannetti N; Edwardes MD; Cecere R; Cantarovich M
    Clin Transplant; 2007; 21(3):305-8. PubMed ID: 17488377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy.
    Falger JC; Mueller T; Arbeiter K; Boehm M; Regele H; Balzar E; Aufricht C
    Pediatr Transplant; 2006 Aug; 10(5):565-9. PubMed ID: 16856992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial.
    De Simone P; Metselaar HJ; Fischer L; Dumortier J; Boudjema K; Hardwigsen J; Rostaing L; De Carlis L; Saliba F; Nevens F
    Liver Transpl; 2009 Oct; 15(10):1262-9. PubMed ID: 19790150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
    Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients.
    Raichlin E; Khalpey Z; Kremers W; Frantz RP; Rodeheffer RJ; Clavell AL; Edwards BS; Kushwaha SS
    Transplantation; 2007 Aug; 84(4):467-74. PubMed ID: 17713429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease.
    Stephany BR; Boumitri M; Budev M; Alao B; Poggio ED
    J Heart Lung Transplant; 2009 Jun; 28(6):564-71. PubMed ID: 19481016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function.
    Watson CJ; Gimson AE; Alexander GJ; Allison ME; Gibbs P; Smith JC; Palmer CR; Bradley JA
    Liver Transpl; 2007 Dec; 13(12):1694-702. PubMed ID: 18044728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sirolimus-based immunosuppression after cardiac transplantation: predictors of recovery from calcineurin inhibitor-induced renal dysfunction.
    Gustafsson F; Ross HJ; Delgado MS; Bernabeo G; Delgado DH
    J Heart Lung Transplant; 2007 Oct; 26(10):998-1003. PubMed ID: 17919619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conversion to sirolimus in pediatric renal transplantation recipients.
    Garcia CD; Bittencourt VB; Alves AB; Garcia VD; Tumelero A; Antonello JS; Malheiros D
    Transplant Proc; 2006; 38(6):1901-3. PubMed ID: 16908317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of sirolimus vs. calcineurin inhibitor-based immunosuppressive therapies in liver transplantation.
    Zaghla H; Selby RR; Chan LS; Kahn JA; Donovan JA; Jabbour N; Genyk Y; Mateo R; Gagandeep S; Sher LS; Ramicone E; Fong TL
    Aliment Pharmacol Ther; 2006 Feb; 23(4):513-20. PubMed ID: 16441472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conversion to sirolimus in pediatric renal transplant patients: a single-center experience.
    Monteverde ML; Ibañez J; Balbarrey Z; Chaparro A; Diaz M; Turconi A
    Pediatr Transplant; 2012 Sep; 16(6):582-8. PubMed ID: 22533794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increase of proteinuria after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft dysfunction.
    Ruiz JC; Campistol JM; Sánchez-Fructuoso A; Rivera C; Oliver J; Ramos D; Campos B; Arias M; Diekmann F
    Nephrol Dial Transplant; 2006 Nov; 21(11):3252-7. PubMed ID: 16954170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intrarenal vascular resistance parameters in kidney transplant patients receiving calcineurin inhibitor-based or sirolimus-based regimens.
    Lee PC; Lee CY; Hu RH; Lo C; Tsai MK; Lee PH
    Nephrol Dial Transplant; 2010 May; 25(5):1675-80. PubMed ID: 20042398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conversion to sirolimus for chronic allograft dysfunction: long-term results confirm predictive value of proteinuria.
    Diekmann F; Budde K; Slowinski T; Oppenheimer F; Fritsche L; Neumayer HH; Campistol JM
    Transpl Int; 2008 Feb; 21(2):152-5. PubMed ID: 18005087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sirolimus as renal and immunological rescue agent in pediatric liver transplant recipients.
    Basso MS; Subramaniam P; Tredger M; Verma A; Heaton N; Rela M; Mieli-Vergani G; Dhawan A
    Pediatr Transplant; 2011 Nov; 15(7):722-7. PubMed ID: 22004546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Five-year follow-up after late conversion from calcineurin inhibitors to sirolimus in patients with chronic renal allograft dysfunction.
    Krüger B; Fischereder M; Jauch KW; Graeb C; Hoffmann U; Böger CA; Banas B; Obed A; Schlitt HJ; Krämer BK
    Transplant Proc; 2007 Mar; 39(2):518-21. PubMed ID: 17362772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.